Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANAB NASDAQ:ARVN NASDAQ:CLLS NASDAQ:SVRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANABAnaptysBio$23.40+0.9%$23.07$12.21▼$40.70$649.53M-0.19405,268 shs472,652 shsARVNArvinas$7.74-0.9%$7.51$5.90▼$29.61$573.39M2.381.33 million shs1.20 million shsCLLSCellectis$2.89-3.0%$2.49$1.10▼$3.35$165.64M3.0372,320 shs149,395 shsSVRASavara$3.56-0.8%$2.87$1.89▼$4.70$620.48M0.561.74 million shs2.01 million shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANABAnaptysBio+1.84%+10.00%+15.37%-0.51%-34.84%ARVNArvinas-0.26%+2.63%+15.02%+5.68%-68.62%CLLSCellectis-2.30%+13.31%+12.03%+124.06%+31.28%SVRASavara-6.27%+0.28%+39.15%+62.44%-16.90%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANABAnaptysBio$23.40+0.9%$23.07$12.21▼$40.70$649.53M-0.19405,268 shs472,652 shsARVNArvinas$7.74-0.9%$7.51$5.90▼$29.61$573.39M2.381.33 million shs1.20 million shsCLLSCellectis$2.89-3.0%$2.49$1.10▼$3.35$165.64M3.0372,320 shs149,395 shsSVRASavara$3.56-0.8%$2.87$1.89▼$4.70$620.48M0.561.74 million shs2.01 million shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANABAnaptysBio+1.84%+10.00%+15.37%-0.51%-34.84%ARVNArvinas-0.26%+2.63%+15.02%+5.68%-68.62%CLLSCellectis-2.30%+13.31%+12.03%+124.06%+31.28%SVRASavara-6.27%+0.28%+39.15%+62.44%-16.90%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANABAnaptysBio 2.80Moderate Buy$46.1397.12% UpsideARVNArvinas 2.55Moderate Buy$19.76155.34% UpsideCLLSCellectis 3.00Buy$4.0038.41% UpsideSVRASavara 2.83Moderate Buy$7.50110.67% UpsideCurrent Analyst Ratings BreakdownLatest CLLS, ANAB, ARVN, and SVRA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/9/2025SVRASavaraGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$8.00 ➝ $11.009/8/2025SVRASavaraOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$6.00 ➝ $8.009/3/2025SVRASavaraHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$5.00 ➝ $8.008/15/2025SVRASavaraOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$5.00 ➝ $6.008/15/2025SVRASavaraHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$2.00 ➝ $5.008/12/2025ANABAnaptysBioUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$18.00 ➝ $20.008/7/2025ANABAnaptysBioWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$40.00 ➝ $45.008/7/2025ARVNArvinasHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$24.00 ➝ $18.008/7/2025ARVNArvinasWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$19.00 ➝ $16.008/7/2025ARVNArvinasGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$16.00 ➝ $15.007/24/2025ANABAnaptysBioJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$42.00 ➝ $80.00(Data available from 9/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANABAnaptysBio$91.28M7.18N/AN/A$2.33 per share10.04ARVNArvinas$263.40M2.16N/AN/A$8.17 per share0.95CLLSCellectis$49.22M3.26N/AN/A$2.36 per share1.22SVRASavaraN/AN/AN/AN/A$1.00 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANABAnaptysBio-$145.23M-$4.48N/AN/AN/A-107.66%-366.98%-30.58%11/4/2025 (Estimated)ARVNArvinas-$198.90M-$1.01N/AN/AN/A-19.47%-12.01%-6.97%10/29/2025 (Estimated)CLLSCellectis-$36.76M-$0.82N/AN/AN/A-100.69%-68.05%-21.53%11/3/2025 (Estimated)SVRASavara-$95.88M-$0.50N/AN/AN/AN/A-69.05%-54.84%11/11/2025 (Estimated)Latest CLLS, ANAB, ARVN, and SVRA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q1 2025SVRASavara-$0.12-$0.14-$0.02-$0.14N/AN/A8/6/2025Q2 2025ANABAnaptysBio-$1.50-$1.34+$0.16-$1.34$11.55 million$22.26 million8/6/2025Q2 2025ARVNArvinas-$0.87-$0.84+$0.03-$0.84$34.42 million$22.40 million8/4/2025Q2 2025CLLSCellectis-$0.15-$0.24-$0.09-$0.24$10.07 million$18.19 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANABAnaptysBioN/AN/AN/AN/AN/AARVNArvinasN/AN/AN/AN/AN/ACLLSCellectisN/AN/AN/AN/AN/ASVRASavaraN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANABAnaptysBioN/A8.228.22ARVNArvinasN/A5.645.64CLLSCellectis0.581.381.38SVRASavara0.2511.0811.08Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANABAnaptysBioN/AARVNArvinas95.19%CLLSCellectis63.90%SVRASavara87.93%Insider OwnershipCompanyInsider OwnershipANABAnaptysBio33.50%ARVNArvinas4.73%CLLSCellectis16.41%SVRASavara5.33%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANABAnaptysBio10028.00 million18.62 millionOptionableARVNArvinas42073.42 million69.95 millionOptionableCLLSCellectis29055.58 million46.46 millionOptionableSVRASavara20172.84 million163.63 millionOptionableCLLS, ANAB, ARVN, and SVRA HeadlinesRecent News About These CompaniesSVRA Class Action Alert: Robbins LLP Reminds Stockholders of the Lead Plaintiff Deadline in the Savara Inc. Securities Class Action LawsuitSeptember 12 at 4:01 PM | globenewswire.comSVRA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Savara Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitSeptember 12 at 12:00 PM | prnewswire.comPortnoy Law Firm Announces Class Action on Behalf of Savara, Inc. InvestorsSeptember 11 at 3:46 PM | globenewswire.comLaw Offices of Howard G. Smith Encourages Savara Inc. (SVRA) Investors To Inquire About Securities Fraud Class ActionSeptember 11 at 1:08 PM | businesswire.comSavara (NASDAQ:SVRA) Given New $11.00 Price Target at GuggenheimSeptember 11 at 9:26 AM | marketbeat.comExome Asset Management LLC Grows Stake in Savara Inc. $SVRASeptember 11 at 6:17 AM | marketbeat.comBrokerages Set Savara Inc. (NASDAQ:SVRA) Price Target at $6.67September 11 at 2:31 AM | americanbankingnews.comSVRA Investors Have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit with the Schall Law FirmSeptember 10 at 2:10 PM | businesswire.comSVRA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Savara Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitSeptember 10 at 12:00 PM | globenewswire.comPomerantz Law Firm Announces the Filing of a Class Action Against Savara Inc. and Certain Officers – SVRASeptember 10 at 10:00 AM | globenewswire.comSavara (NASDAQ:SVRA) Price Target Raised to $8.00 at OppenheimerSeptember 10 at 8:51 AM | marketbeat.comSecurities Fraud Investigation Into Savara Inc. (SVRA) Announced - Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law FirmSeptember 10 at 6:59 AM | tmcnet.comSavara (NASDAQ:SVRA) Price Target Raised to $11.00 at GuggenheimSeptember 10 at 3:05 AM | americanbankingnews.comOppenheimer Forecasts Strong Price Appreciation for Savara (NASDAQ:SVRA) StockSeptember 10 at 2:01 AM | americanbankingnews.comSecurities Fraud Investigation Into Savara Inc. (SVRA) Announced - Investors Who Lost Money Urged To Contact The Law Offices of Frank R. CruzSeptember 9 at 8:57 PM | tmcnet.comSavara Inc. (SVRA) Investors Who Lost Money - Contact Law Offices of Howard G. Smith About Securities Fraud InvestigationSeptember 9 at 8:57 PM | tmcnet.comSVRA Stockholder Notice: Robbins LLP Reminds Investors of the Class Action Lawsuit Against Savara Inc.September 9 at 7:24 PM | globenewswire.comSAVARA ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Savara Inc. and Encourages Investors to Contact the FirmSeptember 9 at 5:22 PM | globenewswire.comSavara Inc. (SVRA) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud InvestigationSeptember 9 at 4:32 PM | businesswire.comSecurities Fraud Investigation Into Savara Inc. (SVRA) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law FirmSeptember 9 at 4:31 PM | businesswire.comSecurities Fraud Investigation Into Savara Inc. (SVRA) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. CruzSeptember 9 at 4:24 PM | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCLLS, ANAB, ARVN, and SVRA Company DescriptionsAnaptysBio NASDAQ:ANAB$23.40 +0.20 (+0.86%) Closing price 04:00 PM EasternExtended Trading$23.40 0.00 (0.00%) As of 07:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.Arvinas NASDAQ:ARVN$7.74 -0.07 (-0.90%) Closing price 04:00 PM EasternExtended Trading$7.77 +0.03 (+0.39%) As of 05:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.Cellectis NASDAQ:CLLS$2.89 -0.09 (-3.02%) Closing price 04:00 PM EasternExtended Trading$2.89 0.00 (0.00%) As of 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.Savara NASDAQ:SVRA$3.56 -0.03 (-0.84%) Closing price 04:00 PM EasternExtended Trading$3.61 +0.05 (+1.38%) As of 07:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Tesla's U.S. Market Is At An 8-Year Low... How Bad Could It Get? Not Just NVDA: 3 Semiconductor Stocks Struggling This Quarter Broadcom Gets Big Upgrades: How High Analysts See Shares Going Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
